November 30, 2016 - By Darrin Black
In a a research note revealed to clients and investors on Wednesday morning, Chardan Capital stated it was upgrading Arbutus Biopharma (NASDAQ:ABUS) stock from a “Neutral” to a “Buy”. The firm has $4.0 target price on ABUS’s stock.
Out of 5 analysts covering Arbutus Biopharma (NASDAQ:ABUS), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. $20.0 is the highest target while $2.75 is the lowest. The $13.75 average target is 418.87% above today’s ($2.65) stock price. Arbutus Biopharma has been the topic of 10 analyst reports since August 7, 2015 according to StockzIntelligence Inc. As per Friday, August 7, the company rating was initiated by Wedbush. As per Friday, August 7, the company rating was initiated by Wedbush. Chardan Capital Markets downgraded the stock to “Sell” rating in Friday, July 8 report. Chardan Capital Markets initiated the stock with “Sell” rating in Monday, May 16 report. Chardan Capital Markets upgraded Arbutus Biopharma Corp (NASDAQ:ABUS) rating on Friday, October 14. Chardan Capital Markets has “Neutral” rating and $3 price target. As per Wednesday, September 2, the company rating was initiated by JMP Securities. The rating was maintained by RBC Capital Markets on Friday, November 6 with “Outperform”. Leerink Swann downgraded Arbutus Biopharma Corp (NASDAQ:ABUS) on Friday, August 5 to “Market Perform” rating. The stock has “Neutral” rating given by Chardan Capital Markets on Thursday, June 16.
The stock decreased 1.85% or $0.05 during the last trading session, hitting $2.65. Arbutus Biopharma Corp (NASDAQ:ABUS) has declined 49.04% since April 27, 2016 and is downtrending. It has underperformed by 54.27% the S&P500.
Analysts await Arbutus Biopharma Corp (NASDAQ:ABUS) to report earnings on March, 8. They expect $-0.35 earnings per share, down 212.90% or $0.66 from last year’s $0.31 per share. After $-0.31 actual earnings per share reported by Arbutus Biopharma Corp for the previous quarter, Wall Street now forecasts 12.90% negative EPS growth.
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The company has a market cap of $148.07 million. The Firm is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection , a disease of the liver caused by the hepatitis B virus (HBV). It currently has negative earnings. It is developing a pipeline focused on advancing Ribo Nucleic Acid interference therapeutics (RNAi) using its Lipid Nanoparticle technology.
According to Zacks Investment Research, “Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company’s products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.”
More important recent Arbutus Biopharma Corp (NASDAQ:ABUS) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on December 29, 2013, also Seekingalpha.com published article titled: “Arbutus Biopharma Corporation Is Poised To Catch Up In The Hepatitis B Race”, Globenewswire.com published: “Tekmira Announces Launch of Arbutus Biopharma, a Hepatitis B Solutions Company” on July 20, 2015. More interesting news about Arbutus Biopharma Corp (NASDAQ:ABUS) was released by: Quotes.Wsj.com and their article: “News Arbutus Biopharma Corp.ABUS” with publication date: August 06, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Darrin Black